BioCentury
ARTICLE | Finance

Ebb & Flow

May 17, 2004 7:00 AM UTC

With 21 U.S. IPOs already floated in the States since last October, European investors have been waiting for the European biotech window to crack open. One could argue talk is still cheap, but many now believe that Europe will see a steady trickle of companies going public in the coming quarters.

In France, cancer companyImmuno-Designed Molecules and in vitro diagnostics play bioMerieux each have filed a Document de Base, the first step in stating an interest to list on the Paris exchange. As an alternative, bioMerieux is considering raising capital from private investors through the sale of a 35% holding in the company. ...